Etodolac

Discontinued Product

Etodolac (Cat. No. 3871) has been withdrawn from sale for commercial reasons.
Description: Selective cyclooxygenase-2 (COX-2) inhibitor; NSAID
Chemical Name: (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
Datasheet
Citations
Reviews
Literature (6)

Biological Activity for Etodolac

Non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2) (IC50 values are 53 and >100 μM for COX-2 and COX-1 respectively). Displays anti-inflammatory effects in both adjuvant arthritic and normal rats.

Technical Data for Etodolac

M. Wt 287.35
Formula C17H21NO3
Storage Store at +4°C
CAS Number 41340-25-4
PubChem ID 3308
InChI Key NNYBQONXHNTVIJ-UHFFFAOYSA-N
Smiles CCC1(CC(O)=O)OCCC3=C1NC2=C(CC)C=CC=C23

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for Etodolac

References are publications that support the biological activity of the product.

Kato et al (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J.Pharm.Pharmacol. 53 1679 PMID: 11804398

Tachibana et al (2003) Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. Pharmacology 68 96 PMID: 12711837

Shi et al (2004) Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats. Acta Pharmacol.Sinica 25 996

View Related Products by Target

View Related Products by Product Action

View all Cyclooxygenase Inhibitors

Keywords: Etodolac, Etodolac supplier, selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, oxygenases, oxidases, nonsteroidal, anti-inflammatory, drug, NSAID, Cyclooxygenase, 3871, Tocris Bioscience

⚠ WARNING: This product can expose you to chemicals including Etodolac, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information, go to www.P65Warnings.ca.gov

Citations for Etodolac

Citations are publications that use Tocris products.

Currently there are no citations for Etodolac.

Reviews for Etodolac

There are currently no reviews for this product. Be the first to review Etodolac and earn rewards!

Have you used Etodolac?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Immunology Product Listing

Immunology Product Listing

A collection of over 190 products for immunology research, the guide includes research tools for the study of:

  • Chemokine and Cytokine Signaling
  • Chemotaxis
  • Complement System
  • Immune Cell Signaling
  • Inflammation
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Parkinson's Poster

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.